...
首页> 外文期刊>Annals of oncology: official journal of the European Society for Medical Oncology >Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation.
【24h】

Improved incidence of pT0 downstaged surgical specimens in locally advanced rectal cancer (LARC) treated with induction oxaliplatin plus 5-fluorouracil and preoperative chemoradiation.

机译:用诱导奥沙利铂加5-氟尿嘧啶和术前放化疗对局部晚期直肠癌(LARC)中pT0降级的手术标本的发生率提高。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To compare efficacy in terms of pathologic response in LARC patients treated with preoperative chemoradiation, with or without a short-intense course of induction oxaliplatin. PATIENTS AND METHODS: From 05/98 to 10/02, 114 patients were treated with preoperative chemoradiation (4500-5040 cGy + oral Tegafur 1200 mg/day) for cT(3)-(4)N(+/x)M(0) rectal cancer. Starting 05/01, 52 consecutive patients additionally received induction FOLFOX-4, oxaliplatin (85 mg/m(2) iv d1), 5-FU (400 mg/m(2) iv bolus d1) and 600 mg/m(2) iv continuous infusion in 22 h with leucovorin (200 mg iv) d1 and d2, every 15 days (2 cycles), followed by the previously described Tegafur chemoradiation regime. Surgery was performed in 5-6 weeks. Pathological assessment investigated post-treatment T and N status in the rectal wall and peri-rectal tissues. RESULTS: Patients, tumor and treatment characteristics were comparable between groups. Incidence of pT(0) specimens was significantly increased by induction FOLFOX-4 (P = 0.006). Total T and N downstaging were 58% versus 75% and 42% versus 40%, respectively (P = ns). T downstaging of > or =2 categories was significantly superior in FOLFOX-4 group (P = 0.029). CONCLUSIONS: Short-intense induction FOLFOX-4 significantly improves pathologic complete response in LARC patients treated with tegafur-sensitized preoperative chemoradiation. The 44% rate of pT(0)-(1) specimens observed in the oxaliplatin group should impulse innovative surgical approaches to promote ano-rectal sphincter conserving protocols.
机译:目的:比较术前放化疗,有或无短程诱导性奥沙利铂治疗的LARC患者在病理反应方面的疗效。患者与方法:从05/98到10/02,对114例患者进行了cT(3)-(4)N(+ / x)M(4500-5040 cGy +口服Tegafur 1200 mg / day)的术前放化疗。 0)直肠癌。从05/01开始,连续52位患者另外接受了诱导剂FOLFOX-4,奥沙利铂(85 mg / m(2)iv d1),5-FU(400 mg / m(2)iv推注d1)和600 mg / m(2 )每15天(2个周期)静脉注射亚叶酸(200 mg iv)d1和d2在22 h内连续输注,然后进行之前所述的Tegafur化学放射治疗。在5-6周内进行手术。病理评估调查了直肠壁和直肠周围组织治疗后T和N的状态。结果:各组之间的患者,肿瘤和治疗特征相当。诱导FOLFOX-4显着增加了pT(0)标本的发生率(P = 0.006)。总的T和N降级分别为58%对75%和42%对40%(P = ns)。 ≥2类的T降级在FOLFOX-4组中明显更好(P = 0.029)。结论:短剂量诱导FOLFOX-4可显着改善经替加氟敏致敏的术前放化疗治疗的LARC患者的病理完全缓解。在奥沙利铂组中观察到的pT(0)-(1)标本的44%率应该推动创新的外科手术方法以促进肛门直肠括约肌保存方案。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号